Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor and Lymphoma Malignancies 1Advanced Solid Neoplasms 1

Interventions

Cisplatin 281pembrolizumab 234Radiotherapy 171Cetuximab 169Carboplatin 123Docetaxel 110Paclitaxel 96Fluorouracil 95Nivolumab 88Radiotherapy, Intensity-Modulated 80Magnetic Resonance Spectroscopy 39durvalumab 36Radiation 33Surgical Procedures, Operative 32Drug Therapy 32Biopsy 28Radiosurgery 25Erlotinib Hydrochloride 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Specimen Handling 22Platinum 22Immunohistochemistry 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Chemoradiotherapy 19Capecitabine 19tremelimumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × TAK-659 × Clear all
NCT02834247 2023-02-08

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Calithera Biosciences, Inc

Phase 1 Terminated
41 enrolled 24 charts
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡